Correlation Between Blood Lipid Levels and Chronic Pancreatitis

A Retrospective Case–Control Study of 48 Cases

Qingqiang Ni, MD, Lin Yun, MD, Rui Xu, MD, and Dong Shang, MD

Abstract: The incidence of chronic pancreatitis (CP) is increasing, and dyslipidemia severely affects the health of middle-aged and elderly people. We investigated the association between blood lipid levels and CP in China. The serum lipid metabolic indices of 48 patients with CP (CP group) and 48 randomly selected healthy individuals were used as the normal control (NC) group. Statistical analyses of the blood lipid data were performed between the 2 groups using the case–control study method.

High-density lipoprotein-cholesterol (HDL-c) levels decreased and fasting blood glucose (GLU) levels increased in the CP group compared with those in the NC group (P < 0.01). Pearson correlation analysis results showed that serum amylase (AMY) was positively correlated with low-density lipoprotein-cholesterol (LDL-c; r = 0.414, P < 0.05), and urine AMY (UAMY) was positively correlated with total cholesterol (TC; r = 0.614, P < 0.01) and LDL-c (r = 0.678, P < 0.01). A binary logistic regression analysis showed that GLU (odds ratio [OR], 5.052; P < 0.01) and TC (OR, 1.074; P < 0.01) may be risk factors for CP, whereas HDL-c may be a CP protective factor (OR, 0.833; P < 0.01).

The HDL-c levels decreased and GLU levels increased in the CP group compared with those in the NC group; AMY was positively correlated with LDL-c and UAMY was positively correlated with TC and LDL-c; GLU and TC may be risk factors for CP; and HDL-c may be a CP protective factor. This may be the first time that such results have been reported. These findings will contribute to primary prevention and control of CP progression.

Correlation Between Blood Lipid Levels and Chronic Pancreatitis

INTRODUCTION

Chronic pancreatitis (CP) refers to limiting, segmental, diffusing, progressive inflammatory damage, necrosis, and interstitial fibrous lesion of the pancreatic parenchyma because of many causes, usually accompanied by stenosis and dilation of the pancreatic duct, pancreatic calcification, and pancreatic stone formation. The necrosis of pancreatic acinar cells, the atrophy or loss of pancreatic islet cells, and extensive interstitial fibrosis will eventually result in the irreversible destruction of the pancreatic morphology and structure as well as exocrine and endocrine pancreatic insufficiency.

The incidence of CP has geographical differences. According to Liao et al, the incidence of CP is approximately 42/100,000 in USA, 26/100,000 in France, and 22/100,000 in Japan; the incidence was the highest in India at approximately 114 to 200/100,000.1–4 The results of a survey performed in 2008 showed that during 10 years between 1994 and 2004, the incidence of CP in 22 hospitals in China was approximately 13/100,000 and showed an increasing trend year by year.5 It was reported that the ages of 50% of patients with CP were 40 to 59 years; patients >60 years of age accounted for 15%; patients <40 accounted for 35%; 79% of patients were males, while 21% were females; the incidence of CP in black people was higher than in white people; and the 5-year survival rate was >95%.6

The etiology of CP is multifactorial, the result of joint action by environmental and genetic factors.7 In North America, CP caused by alcohol abuse accounts for 44.5%, alcoholic CP for 26.9%, and idiopathic CP for 28.6% of cases. Alcohol abuse is the major cause of CP in males, and the ratio of males to females is 59.4%/28.1%; in nonalcohol abuse condition, the ratio of males to females is 18%/36.7%. Idiopathic causes are more common in females, and the male-to-female ratio is 22.6%/35.2%, P < 0.01.8 In western countries, excessive alcohol consumption plays a leading role and accounts for 60% of cases of CP. In China, excess alcohol consumption only accounts for 35% of the cases of CP.9

In China, as quality of life continues to increase, excess alcohol consumption has gradually replaced biliary tract disease as the leading cause of CP in China. According to a multicenter survey on CP in China, CP caused by biliary tract disease accounted for 33.9%, CP caused by long-term excess alcohol consumption for 35.4%, and CP caused by pancreatic trauma for 10.5% of cases.9 The major causes of biliary tract disease include cholecystitis, choledocholithiasis, cholecystitis, dysfunction of the papillary muscle (spasm or stricture), and biliary...
ascariasis. The damage to exocrine pancreatic acinar cells and endocrine islet cells caused by the reflux of bile into the pancreatic duct and fibrosis caused by interstitial fibrous connective tissue proliferation are the major etiologies. A comparison between smokers and nonsmokers showed that the age of onset in smokers was earlier than in nonsmokers, and the incidence of pancreatic calcification and diabetes mellitus was higher in smokers than in nonsmokers. Other reasons such as gene mutation or loss, hypercalcemia, autoimmune diseases, hyperlipidemia, and congenital malformation of the pancreas can also cause CP. However, no studies on the correlation between dyslipidemia and CP have been reported. Whether dyslipidemia is correlated with the development of CP is worthy of further investigation.

Exocrine pancreatic acinar cell damage occurs in the early stage of CP lesions. With disease progression, endocrine islet cells are involved in the late stage, and a large amount of progressive interstitial fibrous tissue proliferation replaces the normal pancreatic parenchyma cells. Based on the histopathological changes to the pancreas, CP can be classified into 3 types.

1. Chronic obstructive pancreatitis: Degeneration, necrosis, and infection of pancreatic parenchyma cells invade the pancreatic duct, thus causing stenosis of the pancreatic duct. Protein plugs are rarely found in the inside tube; the pancreatic duct epithelium is well preserved, there is no stenosis inside the tube, and there is no pancreatic duct calcification.

2. Chronic calcifying pancreatitis: This is the most common type of CP and includes alcoholic CP. The lesion shows a punctate shape. Some dilated branches of the pancreatic duct have irregular morphology. The main pancreatic duct exhibits stenosis, dilation, calcification, or even stones. The epithelial atrophy of the pancreatic duct and ductal protein embolism often occur.

3. Chronic inflammatory pancreatitis: CP resulting from chronic inflammation caused by chronic inflammation of the biliary tract and stenosis induced by scar formation belongs to this type. The presentations are the destruction of pancreatic exocrine parenchymal cells, formation of diffuse fibrosis, and mononuclear cell infiltration.

With the prominence of the problems of population aging, the incidence of CP shows an increasing trend year by year; dyslipidemia also severely affects the health condition of middle-aged and aged people. The relationship between these two warrants attention. Therefore, this study involved case–control studies on the association between blood lipid levels and CP to provide reference bases for the future diagnosis and treatment of CP.

**POPULATION AND METHODS**

**Population**

**General Information**

This case–control study was approved by the Ethics Committee of the First Affiliated Hospital of Dalian Medical University (Dalian, Liaoning, China). Written informed consents were obtained from the patient for publication of this case–control study. A retrospective analysis was performed on the measurement results of 4 blood lipid indicators in 48 patients with CP (CP group) treated in the First Affiliated Hospital of Dalian Medical University between March 2011 and March 2014. In addition, the blood lipid data of 40 healthy individuals who received physical examination in the First Affiliated Hospital of Dalian Medical University between March 2011 and March 2014 were used as the normal control (NC) group. The gender, age, smoking, drinking, and body mass index (BMI) conditions of the NC group were comparable to those of the CP group. Pack-years was calculated as years of smoking multiplied by the average number of packages smoked per day. A package contains 20 cigarettes. The drinking index was calculated as years of drinking multiplied by the average grams of alcohol consumed per day. Subjects were defined as cigarette smokers or alcohol drinkers if they had smoked ≥5 pack-years or had a ≥150 drinking index, respectively. Nineteen of the 48 CP cases were diagnosed with diabetes, and 10 of the 19 cases were administered metformin. Five of the 19 cases were treated with insulin, and 4 of the 19 cases had already been diagnosed with diabetes and were not treated. GLU levels in 10 of the 15 treated cases were controlled to normal levels, whereas 5 cases were poorly controlled.

**Inclusion and Exclusion Criteria**

The inclusion criteria for cases in the CP group were primarily based on the guidelines for the diagnosis and treatment of CP released by the Chinese Society of Digestive Endoscopy in Shanghai in 2012: (1) typical clinical manifestations (eg, recurrent upper abdominal pain, acute pancreatitis); (2) pancreatic calcification, pancreatic duct stones, and pancreatic duct stenosis or dilatation suggested by imaging examination; (3) characteristic changes in pathology; and (4) presentation of exocrine pancreatic insufficiency. Patients with (1) or (3) were confirmed cases, and patients with (1) and (4) were probable cases. The following imaging methods were used to diagnose CP. (1) Endoscopic ultrasonography was used to detect pancreatic stones, dilation of the side branches, stenosis or irregular dilation of the main pancreatic duct, increased pancreatic parenchymal intensity by ultrasound, and pseudocysts. (2) Magnetic resonance imaging/magnetic resonance cholangiopancreatography was used to detect irregular dilation of the pancreatic ducts, focal pancreatic enlargement, parenchymal atrophy, dilation of the biliary duct, peripancreatic fluid, irregular contour of the pancreas, and disruption of the pancreatic duct. (3) Computed tomography was used for pancreatic calcification, irregular dilation of the pancreatic ducts, focal pancreatic enlargement, parenchymal atrophy, dilation of the biliary duct, peripancreatic fluid, irregular contour of the pancreas, and pseudocysts. (4) Endoscopic retrograde cholangiopancreatography was used to assess dilation of and obstruction of side branches, dilation, stenosis, obstruction, calcification and/or stones in the main pancreatic duct, and pseudocysts. The exclusion criteria for cases in the CP group were as follows: patients with insufficient clinical information or without blood lipid indicator measurement.

The inclusion criteria of the NC group were healthy individuals with age, gender, smoking, drinking, and BMI conditions similar to the CP group to minimize the influence of age, gender, smoking, drinking, and BMI on the statistical results. The exclusion criteria of cases in the NC group were as follows: people with bad habits; and people with biliary diseases or a history of biliary diseases shown by physical examination reports.
Methods

Contents of Retrospective Analysis of Cases

GLU and the 4 blood lipid indicators included total cholesterol (TC), triglyceride (TG), low-density lipoprotein-cholesterol (LDL-c), and high-density lipoprotein-cholesterol (HDL-c). The determination criteria were as follows: normal range TC < 200 mg/dL, TG 50 to 150 mg/dL, LDL-c < 120 mg/dL, HDL-c > 40 mg/dL, and GLU 3.9 to 6.1 mmol/L. The Pearson correlation analysis was performed using the binary logistic regression. The analysis of risk factors was performed using the binary logistic regression. P < 0.05 indicated that the difference was statistically significant.

Statistical Analysis

Statistical analysis was performed using the SPSS17.0 software (SPSS Inc, Chicago, IL). The measurement data were presented as mean ± standard deviation. The difference between the 2 groups was performed using the 2 independent samples t test. Count data were examined using the χ² test. Correlation analysis was performed using Pearson correlation analysis. The analysis of risk factors was performed using the binary logistic regression. P < 0.05 indicated that the difference was statistically significant.

RESULTS

Comparison of Gender, Age, Smoking, Drinking, and BMI Conditions Between the CP and NC Groups

There were 48 cases in the CP group, 27 males and 21 females; the mean age was (60.85 ± 13.36) years; there were 18 smokers and 16 drinkers; and the mean BMI was (25.48 ± 4.75) kg/m². There were 40 cases in the NC group, 20 males and 20 females; the mean age was (56.30 ± 10.92) years; there were 11 smokers and 8 drinkers; and the mean BMI was (26.18 ± 4.98) kg/m². The differences in gender, age, smoking, drinking, and BMI between these 2 groups all lacked statistical significance (P > 0.05) and had comparability (Table 1).

Comparison of GLU and Blood Lipid Indicators Between the CP and NC Groups

The TC, TG, and LDL-c levels exhibited no significant difference between the CP and NC groups (P > 0.05), while the levels of HDL-c in the CP group were significantly lower than in the NC group (P < 0.01) and the levels of GLU in the CP group were significantly higher than those in the NC group (P < 0.01) (Table 2).

Pearson Correlation Analysis

Serum amylase (AMY) did not correlate with the TC, TG, and HDL-c levels (P > 0.05) but did exhibit a positive correlation with the LDL-c levels (r = 0.414, P < 0.05). Urine amylase (UMY) did not correlate with the TG and HDL-c levels (P > 0.05) but did exhibit a positive correlation with the TC levels (r = 0.614, P < 0.01) and with the LDL-c levels (r = 0.678, P < 0.01). Lipase did not correlate with the TC, TG, LDL-c, and HDL-c levels (P > 0.05) (Table 3).

Binary Logistic Regression Analysis

Results of binary logistic regression analysis on the correlations between all indicators and the risk of CP showed that after gender, age, smoking, drinking, and BMI were adjusted, GLU and TC may be risk factors for CP and P value is 0.003 and 0.009, respectively (P < 0.01) and odds ratio (OR) value is 5.052 and 1.074, respectively; and HDL-c may be a CP protective factor (OR, 0.833; P < 0.01) (Table 4).

DISCUSSION

With the increasing prominence of the problems of population aging, the incidence and mortality rates of cardiovascular and cerebrovascular diseases caused by atherosclerosis have exhibited an increasing trend year by year. “Blood lipids” is the general term for various lipids in the blood. The level of blood lipids in the body of healthy individuals is maintained at a dynamic balance; the detection of blood lipids can directly reflect the metabolic condition of lipids inside the body. An abnormal lipid metabolism plays an important role in the formation of atherosclerotic plaques. A large number of studies have confirmed that TC, TG, and LDL-c are major risk factors for cardiovascular diseases, whereas HDL-c has a negative correlation with cardiovascular diseases. In clinical contexts, the routine detection of blood lipid indicators has received increasing attention from medical personnel in all departments.

It has been reported that the risk factors for CP development include drinking, smoking, diabetes mellitus, gene mutations of calcium-sensitive receptors, volatile hydrocarbons in occupation, celiac disease, aspirin abuse, chronic renal failure, toxins, recurrent acute pancreatitis, severe acute pancreatitis, pancreatic duct obstruction, hypercalcemia, and hyperlipidemia. The pathogenesis of CP is still not clear. For patients without high risk factors, the current consensus is that alcoholism, biliary pancreatitis, gene mutations [serine protease inhibitor, CFTR (cystic fibrosis transmembrane conductance regulator) gene; protease, serine, 1 (trypsin 1); and serine peptidase inhibitor, Kazal type 1], idiopathic pancreatitis, irregular lifestyles, and autoimmune diseases may be the causes of CP.

A clinical study by Zhang et al showed that compared with healthy individuals, patients with CP had elevated plasma levels of glucose, lactate, creatine, formic acid, glycerol, tyrosine, phenylalanine, lysine, histidine, glutamine, glutamic acid, and

TABLE 1. Comparison of Gender, Age, Smoking, Drinking, and BMI Between the CP and NC Groups

| Item                  | CP Group | NC Group | P Value |
|-----------------------|----------|----------|---------|
| Number of case (male/female) | 48 (27/21) | 40 (20/20) | 0.558   |
| Age, y                | 60.85 ± 13.36 | 56.30 ± 10.92 | 0.088   |
| Smoking (yes/no)      | (18/30)  | (11/29)  | 0.320   |
| Drinking (yes/no)     | (16/32)  | (8/32)   | 0.162   |
| BMI, kg/m²            | 25.48 ± 4.75 | 26.18 ± 4.98 | 0.499   |

BMI = body mass index, CP = chronic pancreatitis, NC group = normal control group.
TABLE 2. Comparison of TC, TG, LDL-c, HDL-c, and GLU Between the CP and NC Groups ($\bar{x} \pm s$)

| Item          | CP Group $\bar{x} \pm s$ | NC Group $\bar{x} \pm s$ | $P$ Value |
|---------------|---------------------------|---------------------------|-----------|
| Number of cases | 48                        | 40                        | —         |
| TC            | 189.60 ± 152.65           | 166.47 ± 21.17            | 0.345     |
| TG            | 126.88 ± 120.71           | 104.58 ± 35.10            | 0.228     |
| LDL-c         | 98.68 ± 30.46             | 97.54 ± 16.58             | 0.825     |
| HDL-c         | 45.29 ± 12.02             | 52.30 ± 9.91              | 0.004     |
| GLU           | 6.59 ± 3.15               | 4.91 ± 0.59               | 0.001     |

CP = chronic pancreatitis, GLU = fasting blood glucose, HDL-c = high-density lipoprotein-cholesterol, LDL-c = low-density lipoprotein-cholesterol, NC group = normal control group, TC = total cholesterol, TG = triglyceride.

TABLE 3. Pearson Correlation Analyses Between AMY, UAMY, Lipase, and Blood Lipid of Patients in the CP Group

| Variable | AMY | UAMY | Lipase |
|----------|-----|------|--------|
|          | $r$ Value | $P$ Value | $r$ Value | $P$ Value | $r$ Value | $P$ Value |
| TC       | 0.341 | 0.065 | 0.614 | 0.009 | 0.123 | 0.525 |
| TG       | 0.120 | 0.528 | 0.250 | 0.334 | 0.108 | 0.578 |
| LDL-c    | 0.414 | 0.023 | 0.678 | 0.003 | 0.213 | 0.266 |
| HDL-c    | 0.170 | 0.371 | 0.287 | 0.263 | 0.048 | 0.804 |

AMY = serum amylase, CP = chronic pancreatitis, HDL-c = high-density lipoprotein-cholesterol, LDL-c = low-density lipoprotein-cholesterol, TC = total cholesterol, TG = triglyceride, UAMY = urine amylase.
TC were 1.074 and 1.076, respectively. These data suggest that GLU and TC may be the risk factors for CP and that HDL-c may be a protective factor for CP, regardless of whether the 2 steatorrhea cases were included. It has been reported that steatorrhea develops when lipase output is <10% than that of normal output. Quantifying fecal fat is the gold standard for diagnosing pancreatic exocrine insufficiency. However, this method requires a strict diet of 100 g fat/d for 5 days, and feces from the last 3 days must be collected. Thus, a major drawback is that the process is cumbersome and unpleasant for both laboratory personnel and patients. Therefore, this method is only available at a few specialized centers. Moreover, quantifying fecal fat is a common way to evaluate fat malabsorption in patients with CP. However, almost no data have been reported on the correlation between steatorrhea and HDL-c. To the best of our knowledge, no previous domestic or international report had shown similar conclusions. Therefore, we speculated that the increased HDL-c levels and decreased GLU or/and TC levels may exert a certain preventive and protective effect on the development of CP. Before application of this conclusion in clinical practice, we suggest that researchers conduct further multicenter and large sample cohort studies for verification.

CONCLUSION

The HDL-c levels decreased and GLU levels increased in the CP group compared with those in the NC group; AMY was positively correlated with LDL-c and UAMY was positively correlated with TC and LDL-c; GLU and TC may be risk factors for CP; and HDL-c may be a CP protective factor. This may be the first time that such results have been reported. These findings will contribute to primary prevention and control of CP progression.

REFERENCES

1. Garg PK, Tandon RK. Survey on chronic pancreatitis in the Asia-Pacific region. J Gastroenterol Hepatol. 2004;19:998–1004.
2. Liao Z, Jin G, Cai D, et al. Guidelines: diagnosis and therapy for chronic pancreatitis. J Interiv Gastroenterol. 2013;3:133–136.
3. Levy P, Barthe M, Mollard BR, et al. Estimation of the prevalence and incidence of chronic pancreatitis and its complications. Gastroenterol Clin Biol. 2006;30:838–844.
4. Tandon RK, Sato N, Garg PK. Chronic pancreatitis: Asia-Pacific consensus report. J Gastroenterol Hepatol. 2002;17:508–518.
5. Wang LW, Li ZS, Li SD, et al. Prevalence and clinical features of chronic pancreatitis in China: a retrospective multicenter analysis over 10 years. Pancreas. 2009;38:248–254.
6. Raimondi S, Lowenfels AB, Morselli-Labate AM, et al. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol. 2010;24:349–358.
7. Braganza JM, Lee SH, McCoy RF, et al. Chronic pancreatitis. Lancet. 2011;377:1184–1197.
8. Cote GA, Yadav D, Silvia A, et al. Alcohol and smoking as risk factors in an epidemiology study of patients with chronic pancreatitis. Clin Gastroenterol Hepatol. 2011;9:266–273.
9. Luowei W, Zhaoshen L, Shude L, et al. A multi-center survey on chronic pancreatitis in China. Chin J Pancreatol. 2007;7:1–5.
10. Wang W, Guo Y, Liao Z, et al. Occurrence of and risk factors for diabetes mellitus in Chinese patients with chronic pancreatitis. Pancreas. 2011;40:206–212.
11. Xiaoping C. Surgery. Beijing: People’s Medical Publishing House; 2010:667–669.
12. Chen H, Chen Y, Jin X, et al. A survey on blood lipid levels among newborns and healthy inhabitants in urban Shanghai (2008–2009). J Clin Lipidol. 2011;5:380–386.
13. Ballantyne CM, Hoogeveen RC. Role of lipid and lipoprotein profiles in risk assessment and therapy. Am Heart J. 2003;146:227–233.
14. Bruckert E, Czernichow S, Bertrais S, et al. Blood lipid and lipoprotein levels: relationships with educational level and region of residence in the French SU.VI.MAX study Prev Med. 2005;40:803–811.
15. Hokanson JE, Austin MA. Plasma triglyceride level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213–219.
16. DiMagno MJ, DiMagno EP. Chronic pancreatitis. Curr Opin Gastroenterol. 2012;28:523–531.
17. Felderbauser P, Klein W, Bulut K, et al. Mutations in the calcium-sensing receptor: a new genetic risk factor for chronic pancreatitis? Scand J Gastroenterol. 2006;41:343–348.
18. Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology. 2001;120:682–707.
19. Pezzilli R. Etiology of chronic pancreatitis: has it changed in the last decade? World J Gastroenterol. 2009;15:4737–4740.

20. Zhang L, Jin H, Guo X, et al. Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by (1) H nuclear magnetic resonance-based metabonomic profiles. Clin Biochem. 2012;45:1064–1069.

21. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58:342–374.

22. Navab M, Hama-Levy S, Van Lenten BJ, et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 1997;99:2005–2019.

23. Van Lenten BJ, Wagner AC, Nayak DP, et al. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation. 2001;103:2283–2288.

24. Hartge MM, Unger T, Kintscher U. The endothelium and vascular inflammation in diabetes. Diab Vasc Dis Res. 2007;4:84–88.

25. Yadav R, Bhartiya JP, Verma SK, et al. The evaluation of serum amylase in the patients of type 2 diabetes mellitus, with a possible correlation with the pancreatic functions. J Clin Diagn Res. 2013;7:1291–1294.

26. Yingjie M, Suping F, Lifeng F, et al. Blood lipid levels and clinical analysis of hyperlipidemic patients with acute pancreatitis. J Clin Inter Med. 2005;22:120–121.

27. DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. N Engl J Med. 1973;288:813–815.

28. Van De Kamer JH, Ten Bokkel Huinink H, Weyers HA. Rapid method for the determination of fat in feces. J Biol Chem. 1949;177:347–355.